1. Petar P, Beaman BL, Ravalison M, et al. Nocardia and actinomyces. In: Yi-Wei Tang, Dongyou Liu, Max Sussman, Ian Poxton, Joseph Schwartzman eds. Mol Med Microbiol. 2nd edition.
London, Academic Press; 2015.
2. Tian X, Teo WFA, Wee WY, et al. Genome characterization and taxonomy of Actinomyces acetigenes sp. nov., and Actinomyces stomatis sp. nov., previously isolated from the human oral
cavity. BMC Genomics 2023; 24: 734-749.
3. Samaranayake L. Actinomycetes, clostridia and Bacillus species. In: Essential Microbiology for Dentistry. 5th Edition. Edinburgh, UK: Elsevier; 2018.
4. Valour F, Sénéchal A, Dupieux C, et al. Actinomycosis: etiology, clinical features, diagnosis, treatment, and management. Infect Drug Resist 2014; 7: 183-197.
5. Kononen E., Wade W. G. Actinomyces and related organisms in human infections. Clinical Microbiology Reviews 2015; 28: 419–442.
6. Rolfe R, Steed LL, Salgado et al. Actinomyces meyeri, a Common Agent of Actinomycosis. Am J Med Sci 2016; 352: 53-62.
7. Li J, Li Y, Zhou Y, et al. Actinomyces and Alimentary Tract Diseases: A Review of Its Biological Functions and Pathology. Biomed Res Int 2018; 26: 3820215.
8. Gajdács M, Urbán E, Terhes G. Microbiological and Clinical Aspects of Cervicofacial Actinomyces Infections: An Overview. Dent J 2019; 7: 85-101.
9. TortoriCi S, Burruano f, BuzzanCa ML, et al. Cervico-Facial Actinomycosis: Epidemiological and clinical Comments. Am J Infect Dis 2008; 4: 204–208.
10. Karanfilian KM, Valentin MN, Kapila R, et al. Cervicofacial actinomycosis. Int J Dermatol 2020; 59: 1185-1190.
11. Brosig AM, Hitzenbichler F, Ernst B, et al. Cervicofacial actinomycosis. Laryngorhinootologie 2021; 100: 966-972.
12. Boot M, Archer J, Ali I. The diagnosis and management of pulmonary actinomycosis. J Infect Public Health 2023; 16: 490-500.
13. Martínez-Girón R, Pantanowitz L. Pulmonary actinomycosis: cytomorphological features. Monaldi Arch Chest Dis 2021; 92: 1641-1648.
14. Ferjaoui MA, Arfaoui R, Khedhri S, et al. Pelvic actinomycosis: A confusing diagnosis. Int J Surg Case 2021; 86: 106387.
15. Meena DS, Kumar D, Sharma M, et al. The epidemiology, clinical presentation and treatment outcomes in CNS actinomycosis: a systematic review of reported cases. Orphanet J Rare Dis 2023;
18: 133-143.
16. Barberis, C.; Budia, M. Palombarani, et al. Antimicrobial susceptibility of clinical isolates of Actinomyces and related genera reveals an unusual clindamycin resistance among Actinomyces
urogenitalis strains. J Glob Antimicrob Resist 2017; 8: 115–120.
17. Mochon AB, Sussland D, Saubolle MA. Aerobic Actinomycetes of Clinical Significance. Microbiol Spectr 2016; 4.
18. Lin WV, Kruse RL, Yang K, et al. Diagnosis and management of pulmonary infection due to Rhodococcus equi. Clin Microbiol Infect 2019; 25: 310-315.
19. Bonifaz A, Tirado-Sánchez A, Vazquez-Gonzalez D, et al. Actinomycetoma by Actinomadura madurae: Clinical Characteristics and Treatment of 47 Cases. Indian Dermatol Online J 2021;
12: 285-289.
20. Gras E, Bergeron E, Puges M, et al. Identification of Streptomyces spp. in a Clinical Sample: Always Contamination? Results of a French Retrospective Study. Open Forum Infect Dis 2022; 9:
ofac271.
21. Roth A, Andrees S, Kroppenstedt RM, et al. Phylogeny of the genus Nocardia based on reassessed 16S rRNA gene sequences reveals underspeciation and division of strains classified as No-
cardia asteroides into three established species and two unnamed taxons. J Clin Microbiol 2003; 41: 851-856.
22. Chen B, Tang J, Lu Z, et al. Primary cutaneous nocardiosis in a patient with nephrotic syndrome: a case report and review of the literature. Medicine (Baltimore, MD) 2016; 95: e2490.
23. Wilson JW. Nocardiosis: updates and clinical overview. Mayo Clin Proc 2012; 87: 403-407.
24. Matsumoto T, Shimizu T, Aoshima Y, et al. Endobronchial hamartoma with obstructive pneumonia due to Nocardia asiatica. Gen Thorac Cardiovasc Surg 2011; 59: 141-144.
25. Hamid ME, AI Azraqi TA, Joseph MR, et al. Isolation of a rare Nocardia wallacei from an HIV-positive patient with pulmonary infection in southern Saudi Arabia. Saudi Med J 2013; 34:644-
647.
26. Makadia S, Patel I, Soosaipillai I, et al. First Case of Nocardia pseudobrasiliensis Causing Primary Cutaneous Nocardiosis in an Immunocompetent Patient. J Investig Med High Impact Case
Rep 2020; 8: 1-4.
27. Conville PS, Brown-Elliott BA, Smith T, et al. The Complexities of Nocardia Taxonomy and Identification. J Clin Microbiol. 2017; 56: e01419-17.
28. Saubolle MA, Sussland D. Nocardiosis: review of clinical and laboratory experience. J Clin Microbiol 2003; 41: 4497–4501.
29. Ambrosioni J, Lew D, Garbino J. Nocardiosis: updated clinical review and experience at a tertiary center. Infection 2010; 38: 89–97.
30. Dorman SE, Guide SV, Conville PS, et al. Nocardia infection in chronic granulomatous disease. Clin Infect Dis 2002; 35: 390–394.
31. Peleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007;
44: 1307–1314.
32. Ali T, Chakraburtty A, Mahmood S, et al. Risk of nocardial infections with anti-tumor necrosis factor therapy. Am J Med Sci 2013; 346: 166–168.
33. Filice GA, Niewoehner DE. Contribution of neutrophils and cell-mediated immunity to control of Nocardia asteroides in murine lungs. J Infect Dis 1987; 156: 113-121.
34. Brown-Elliott BA, Brown JM, Conville PS, et al. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev 2006; 19: 259-282.
35. Coussement J, Lebeaux D, van Delden C, et al. Nocardia infection in solid organ transplant recipients: a multicenter European case-control study. Clin Infect Dis 2016; 63: 338–345.
36. Hodille E, Prudhomme C, Dumitrescu O, et al. Rapid, Easy, and Reliable Identification of Nocardia sp. by MALDI-TOF Mass Spectrometry, VITEK®-MS IVD V3.2 Database, Using Direct
Deposit. International Journal of Molecular Sciences 2023; 24: 5469.
37. Rathish B, Zito PM. In: Salah Aboubakr ed. Nocardia. StatPearls Treasure Island (FL): StatPearls Publishing; 2024.
38. Woods GL, Brown-Elliott BA, Conville PS, et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes. 2nd ed. Wayne (PA): Clinical and Laboratory Standards
Institute; March 2011.
39. Uhde KB, Pathak S, McCullum I Jr, et al. Antimicrobial-resistant nocardia isolates, United States, 1995-2004. Clin Infect Dis. 2010; 51: 1445-1448.
40. Lederman ER, Crum NF. A case series and focused review of nocardiosis: clinical and microbiologic aspects. Medicine (Baltimore) 2004; 83: 300–313.
41. Jodlowski TZ, Melnychuk I, Conry J. Linezolid for the treatment of Nocardia spp. infections. Ann Pharmacother 2007; 41: 1694-1699.
42. Van Dijk K, van Kessel DA, Schijffelen MJ, et al. Disseminated Nocardia infection: spontaneous resolution in response to decrease of immunosuppression. New Microbes New Infect 2015; 3:
10–11.
43. Traxler RM, Bell ME, Lasker B, et al. Updated Review on Nocardia Species: 2006-2021. Clin Microbiol Rev 2022; 35: e0002721.
44. Coussement J, De Greef J, Dureault A, et al. Can we kill two birds with this stone? Anti-pneumocystis prophylaxis to prevent Nocardia infection in hematopoietic stem cell transplant reci-
pients. Biol Blood Marrow Transplant 2018; 24: 1952–1953.
45. Goodlet KJ, Tokman S, Nasar A, et al. Nocardia prophylaxis, treatment, and outcomes of infection in lung transplant recipients: A matched case-control study. Transpl Infect Dis. 2021; 23:
e13478.